



“IDH Mutant Gliomagenesis”



Nduka Amankulor, MD
Assistant Professor, Dept of Neurosurgery
University of Pittsburgh

Wednesday, April 9, 2014, 8:00 am, Brady Auditorium, Room B131

This course will fulfill the licensure requirement set forth by the State of Connecticut. This Grand Rounds Activity is not supported by any Educational Grant.

NEEDS ASSESSMENT

The lecture is required to help physicians understand how IDH mutation status impacts medical decision-making, especially with regard to the therapeutic options available for patients with glioma.

LEARNING OBJECTIVES

At the conclusion of this activity, participants will understand:

- The role of IDH Mutations in Glioma Diagnosis
- Modalities for IDH Mutation Detection
- Immunologic Consequences of IDH Mutations

ACCREDITATION

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

FACULTY DISCLOSURES

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.

DESIGNATION STATEMENT

The Yale School of Medicine designates this educational activity for 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim credit commensurate with the extent of their participation in the activity.